Release of securities from Escrow

Melbourne (Australia) – 22nd December 2017. Further to the pre-quotation disclosure made on 15 November 2017, Telix Pharmaceuticals Limited (ASX.TLX) ("**Telix**", the "**Company**"), advises pursuant to ASX Listing Rule 3.10A, that 37,031,165 shares which were classed as restricted securities and subject to ASX-imposed mandatory escrow, are due be released from mandatory escrow on 15 January 2018.

These securities are also subject to various voluntary escrow restrictions as detailed in the company's Prospectus dated 16 October 2017.

About Telix Pharmaceuticals Limited

Telix is an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR). The Company is developing an advanced portfolio of oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX).

For more information visit www.telixpharma.com.

Corporate Contact
Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
Email: chris@telixpharma.com

Investor and Media Relations
Kyahn Williamson
WE Buchan
Tel: +61 (3) 9866 4722
Email: kwilliamson@buchanwe.com.au